Skip to content

Comparative Study of Zataria Multiflora Boiss Vaginal Cream and Clotrimazol in Candida Vaginitis treatment

Comparison of Eeffect of Zataria Multiflora Boiss Vaginal Cream with Clotrimazol Vaginal Cream in Candida Vaginitis Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138807112537N1
Enrollment
73
Registered
2010-01-30
Start date
2003-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Candida Vaginitis. Candidiasis of Vulva and Vagina

Interventions

Intervention 1: Herbal vaginal cream, made of Avishan Shirazi (1%) (Zataria Multiflora Boiss), one applicator every night, for 1 Week. Intervention 2: Clotrimazole, vaginal Cream, one applicator every
Treatment - Drugs
Herbal vaginal cream, made of Avishan Shirazi (1%) (Zataria Multiflora Boiss), one applicator every night, for 1 Week
Clotrimazole, vaginal Cream, one applicator every night, for 1 Week

Sponsors

Vice-chancellor for Research, Jondishapour University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: signs and symptoms of Candida vaginitis, positive direct smear of vaginal discharge Exclusion criteria: pregnant women, low compliance, any drug hypersensitivity, recurrent Candida vaginitis (4 or more Candida vaginitis in a year), consumption of immunosuppressive drug or widespread antibiotics, history of epilepsy, diabetes, heart disease, high blood pressure, thyroid diseases, or advanced arthritis, using other vaginal creams or suppositories during the study period, consumption of systemic antifungal drugs during 4 weeks prior to the study, presence of non-candidal vaginitis, consumption of oral contraceptives.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Discharge. Timepoint: Baseline and3 to 4 Days after treatment. Method of measurement: Clinical Examination, observation, and medical history.;Pruritus. Timepoint: Baseline and 3 to 4 Days after treatment. Method of measurement: History.;Edema. Timepoint: Baseline and 3 to 4 Days after treatment. Method of measurement: Clinical Examination, observation, and medical history.;Erythema symptoma. Timepoint: Baseline and 3 to 4 Days after treatment. Method of measurement: Clinical Examination, Observation, and History.;Dysuria Symptom. Timepoint: Baseline and 3-4 Days after treatment. Method of measurement: History.;Dysparonia Symptom. Timepoint: Baseline and 3 to 4 Days after the treatment. Method of measurement: History.;Culture results. Timepoint: 3 to 4 Days after Treatment. Method of measurement: Wet Smear and Vaginal Culture.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Fouladi

Tehran University of Medical Sciences

zfouladi2000@yahoo.com+98 21 5539 7347

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026